1Van Belzen M, Bartsch O, Lacombe D et al. Rubinstein-Taybi syndrome (CREBBP, EP300). Eur J Hum Genet 2011; 19: 118–20.
PubMed Web of Science® Google Scholar
2Van de Kar AL, Houge G, Shaw AC et al. Keloids in Rubinstein–Taybi syndrome: a clinical study. Br J Dermatol 2014; 171: 615–21.
10.1111/bjd.13124
PubMed Web of Science® Google Scholar
3Madu P, Kundu RV. Follicular and scarring disorders in skin of color: presentation and management. Am J Clin Dermatol 2014; 15: 307–21.
10.1007/s40257-014-0072-x
PubMed Web of Science® Google Scholar
4Marneros AG, Norris JE, Olsen BR, Reichenberger E. Clinical genetics of familial keloids. Arch Dermatol 2001; 137: 1429–34.
10.1001/archderm.137.11.1429
CAS PubMed Web of Science® Google Scholar
5Marneros AG, Norris JE, Watanabe S et al. Genome scans provide evidence for keloid susceptibility loci on chromosomes 2q23 and 7p11. J Invest Dermatol 2004; 122: 1126–32.
10.1111/j.0022-202X.2004.22327.x
CAS PubMed Web of Science® Google Scholar
6Yan X, Gao J, Chen Y et al. [Preliminary linkage analysis and mapping of keloid susceptibility locus in a Chinese pedigree]. Zhonghua Zheng Xing Wai Ke Za Zhi 2007; 23: 32–5 (in Chinese).
PubMed Web of Science® Google Scholar
7Saroja AO, Naik KR, Nalini A, Gayathri N. Bethlem myopathy: an autosomal dominant myopathy with flexion contractures, keloids, and follicular hyperkeratosis. Ann Indian Acad Neurol 2013; 16: 712–15.
10.4103/0972-2327.120453
PubMed Web of Science® Google Scholar
8Arno AI, Gauglitz GG, Barret JP, Jeschke MG.Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns 2014; pii: S0305-4179(14)00071-0.
10.1016/j.burns.2014.02.011
Web of Science® Google Scholar
9Hahn JM, Glaser K, McFarland KL et al. Keloid-derived keratinocytes exhibit an abnormal gene expression profile consistent with a distinct causal role in keloid pathology. Wound Repair Regen 2013; 21: 530–44.
10.1111/wrr.12060
PubMed Web of Science® Google Scholar
10Lee TY, Chin GS, Kim WJ et al. Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg 1999; 43: 179–84.
10.1097/00000637-199943020-00013
CAS PubMed Web of Science® Google Scholar
11Arno AI, Gauglitz GG, Barret JP, Jeschke MG. New molecular medicine-based scar management strategies. Burns 2014; 40: 539–51.
10.1016/j.burns.2013.11.010
PubMed Web of Science® Google Scholar
12Totan S, Echo A, Yuksel E. Heat shock proteins modulate keloid formation. Eplasty 2011; 11: e21.
PubMed Google Scholar
13González-Ramos M, Calleros L, López-Ongil S et al. HSP70 increases extracellular matrix production by human vascular smooth muscle through TGF-β1 up-regulation. Int J Biochem Cell Biol 2013; 45: 232–42.
10.1016/j.biocel.2012.10.001
CAS PubMed Web of Science® Google Scholar
14Van den Broek LJ, Limandjaja GC, Niessen FB, Gibbs S. Human hypertrophic and keloid scar models: principles, limitations and future challenges from a tissue engineering perspective. Exp Dermatol 2014; 23: 382–6.
10.1111/exd.12419
CAS PubMed Web of Science® Google Scholar

Citing Literature

Volume171, Issue3

September 2014

Pages 452-453

Rare genetic diseases, signalling pathways, and keloid scar formation

Abstract

References

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Rare genetic diseases, signalling pathways, and keloid scar formation

Abstract

References

Citing Literature

References

Related

Information